Company Filing History:
Years Active: 2015-2020
Title: Clive H Reading: Innovator in Topical Estrogen Formulations
Introduction
Clive H Reading is a notable inventor based in Kent, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of topical formulations for the treatment of dry eye syndrome. With a total of 2 patents, his work focuses on innovative solutions that address common ocular conditions.
Latest Patents
Clive H Reading's latest patents include groundbreaking formulations for the topical application of estrogen and estrogen analogs. These formulations are designed for the treatment of primary or secondary dry eye syndrome, also known as keratoconjunctivitis sicca (KCS). The preferred formulations utilize 17-β-estradiol and its derivatives, which can be delivered in lipid, liposomes, polymers, or aqueous and non-aqueous vehicles. These time-release and micro-dose formulations are particularly effective for treating the ocular surface tissues and may also benefit patients undergoing post-operative refractive surgery and corneal transplants.
Career Highlights
Throughout his career, Clive has worked with various companies, including Altos Vision Limited and Redwood Pharma AB. His experience in these organizations has allowed him to refine his expertise in pharmaceutical formulations and contribute to advancements in ocular health.
Collaborations
Clive H Reading has collaborated with notable professionals in his field, including Thomas L Rowe and Mario G Fsadni. These partnerships have facilitated the exchange of ideas and innovations, further enhancing the impact of his work.
Conclusion
Clive H Reading stands out as an influential inventor in the realm of topical estrogen formulations. His innovative patents and collaborations reflect his commitment to improving treatments for dry eye syndrome and related conditions.